Volume 3.13 | Apr 13

Prostate Cell News 3.13 April 13, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Suppression of Tak1 Promotes Prostate Tumorigenesis
Researchers present findings that functionally validate a proposed tumor suppressor role of TGF-β activated kinase-1 (Tak1) in prostate cancer. [Cancer Res] Abstract

Register for Free Webinar April 17: PneumaCult™-ALI for Bronchial Epithelial Cells.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Simultaneous Inhibition of Two Regulatory T-Cell Subsets Enhanced Interleukin-15 Efficacy in a Prostate Tumor Model
Investigators evaluated interleukin-15 combined with antibodies to block negative immune regulator cytotoxic T lymphocyte antigen 4 and programmed death ligand 1 in an established murine transgenic adenocarcinoma of mouse prostate (TRAMP)-C2 prostate tumor model. [Proc Natl Acad Sci USA] Abstract

Knockdown of AGR2 Induces Cellular Senescence in Prostate Cancer Cells
A potential role of anterior-gradient 2 (AGR2) in cellular senescence was investigated. [Carcinogenesis] Abstract

Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia: The Role of Stromal Androgen Receptor in Macrophage-Induced Prostate Stromal Cell Proliferation
This study provides mechanistic insights on the regulation of prostate stromal cells by macrophages via stromal androgen receptor/CCL3 signaling pathways. [J Biol Chem] Abstract

Mechanism of β-Catenin Mediated Transcriptional Regulation of EGFR Expression in GSK3β Inactivated Prostate Cancer Cells
Scientists report the mechanism of epidermal growth factor receptor (EGFR) expression by transcriptionally active β-catenin in GSK3β-inactivated prostate cancer cells that eventually leads to its enhanced proliferation and survival. [J Biol Chem] Abstract

MicroRNA Let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth
The researchers intended to identify and characterize microRNA let-7c as a potential tumor suppressor in prostate cancer. [PLoS One] Abstract

Effects of Lysophosphatidic Acid on Calpain-Mediated Proteolysis of Focal Adhesion Kinase in Human Prostate Cancer Cells
The effects of lysophosphatidic acid on calpain-mediated proteolysis were examined in a PC-3 human prostate cancer cell line. [Prostate] Abstract

Small Molecule Tolfenamic Acid Inhibits PC-3 Cell Proliferation and Invasion In Vitro, and Tumor Growth in Orthotopic Mouse Model for Prostate Cancer
Researchers evaluated the anti-cancer activity of tolfenamic acid using in vitro and in vivo models for prostate cancer. [Prostate] Abstract

Hemostatic Gelatin Sponge Is a Superior Matrix to Matrigel for Establishment of LNCaP Human Prostate Cancer in Nude Mice
Scientists compared tumor development and growth of LNCaP human prostate cancer cells mixed with Matrigel or in gelatin sponges. [Prostate] Abstract

Antiproliferative Effect of Oleuropein in Prostate Cell Lines
Researchers investigated the effects of oleuropein on LNCaP and DU145 prostate cancer cell lines and on BPH-1 non-malignant cells. [Int J Oncol] Abstract

CLINICAL RESEARCH

Long-Term Dynamics of Bone Mineral Density during Intermittent Androgen Deprivation for Men with Nonmetastatic, Hormone-Sensitive Prostate Cancer
Changes in bone mineral density and fracture risk in men who received intermittent androgen deprivation for nonmetastatic, hormone-sensitive prostate cancer were investigated. [J Clin Oncol] Abstract

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Scientists aimed to determine the effect of hypoxia in patients with prostate cancer treated with radiotherapy. [Clin Cancer Res] Abstract | Press Release

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal

SCIENCE NEWS
Merrimack Pharmaceuticals’ Therapies Show Promise in Certain Advanced Breast, Gastric and Gynecologic Cancers
Merrimack Pharmaceuticals, Inc. announced the presentation of Phase I safety and clinical results evaluating two potential new therapies with a novel target – ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies including breast, ovarian, gastric, esophageal and bladder cancers. The two studies were presented in poster sessions at the European Society for Medical Oncology in Vienna, Austria. [Merrimack Pharmaceuticals, Inc.] Press Release
INDUSTRY NEWS

Prostate Cancer Foundation and Stand Up To Cancer Announce New Dream Team
The Prostate Cancer Foundation, Stand Up To Cancer and the American Association for Cancer Research announced the formation of a new Dream Team dedicated to prostate cancer research. [Prostate Cancer Foundation] Press Release

Metamark Genetics Completes Proof-of-Concept for Protein-Based Prostate Cancer Test
Metamark Genetics, Inc. announced the successful completion of proof-of-concept for its biomarker prognostic test for prostate cancer. [Metamark Genetics, Inc.] Press Release

GTx Submits Clinical Hold Complete Response Letter to FDA for Its Planned Phase II Clinical Study of Capesaris® for Secondary Hormonal Therapy of Advanced Prostate Cancer
GTx, Inc. announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a complete response to the FDA’s letter regarding the previously announced Full Clinical Hold of the Company’s clinical trials evaluating Capesaris® for primary androgen deprivation therapy for advanced prostate cancer and secondary hormonal therapy. [GTx, Inc.] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW Virtual Prostate Summit: Overcoming the Challenges
April 17, 9:00AM (ET in US)
Webinar

Visit our events page to see a complete list of events in the prostate cell community.
JOB OPPORTUNITIES

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)


Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow (Louisiana State University Health Sciences Center) 


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us